articleThe Lancet NeurologyJan 22, 2014Closed access

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

CCChristian ConfavreuxPOPaul O’ConnorGCGıancarlo ComıMFMark FreedmanAMAaron Miller

Université Claude Bernard Lyon 1 · University of Toronto · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

570
total citations
FWCI
40.68
Percentile
100%
References
19
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Teriflunomide
  • Double blind
  • Multiple sclerosis
  • Medicine
  • Placebo
  • Internal medicine
  • Physical therapy
  • Alternative medicine
No related works found for this paper.

Funding